Challenging Cases in BRAF-Mutated Melanoma: Applying the Latest Advances to Optimize Care

Author(s)/Faculty: Adil Daud, MD, MBBS; Michael A. Davies, MD, PhD
Release Date: 12/22/2021Expiration Date: 12/21/2022
Credit Type: CMENumber of Credits: 1
Content Type: LectureProvider:
Advances in BRAF-targeted agents and their integration into treatment algorithms for patients with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. Although the rapid expansion in available treatment options has improved patient outcomes, physicians are now challenged to select from multiple classes of therapies and combinations, particularly with the increased use of triple therapy regimens combining PD-1 blockade with BRAF/MEK inhibitors. Additionally, the optimal sequencing of regimens for treating advanced BRAF-mutated melanoma remains an active area of investigation. In this case-based educational activity, experts review clinical examples that highlight patients with BRAF-positive melanoma who may benefit from neoadjuvant and/or adjuvant treatment. Faculty also discuss the latest evidence regarding the use of triple therapy for patients with BRAF-mutated melanoma as well as updates on the management of patients with brain metastases.